Regent Peak Wealth Advisors LLC Has $727,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

Regent Peak Wealth Advisors LLC lessened its holdings in Amgen Inc. (NASDAQ:AMGN) by 66.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,790 shares of the medical research company’s stock after selling 5,525 shares during the period. Regent Peak Wealth Advisors LLC’s holdings in Amgen were worth $727,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of AMGN. Diversified Trust Co increased its holdings in Amgen by 16.2% in the 4th quarter. Diversified Trust Co now owns 36,855 shares of the medical research company’s stock worth $9,606,000 after purchasing an additional 5,126 shares in the last quarter. Bangor Savings Bank increased its stake in shares of Amgen by 1.1% in the fourth quarter. Bangor Savings Bank now owns 6,278 shares of the medical research company’s stock valued at $1,636,000 after buying an additional 66 shares during the period. Insight Wealth Strategies LLC raised its holdings in Amgen by 14.6% in the 4th quarter. Insight Wealth Strategies LLC now owns 14,596 shares of the medical research company’s stock valued at $3,804,000 after buying an additional 1,863 shares during the last quarter. Doliver Advisors LP boosted its position in Amgen by 1.1% during the 4th quarter. Doliver Advisors LP now owns 5,751 shares of the medical research company’s stock worth $1,499,000 after buying an additional 65 shares during the period. Finally, Neville Rodie & Shaw Inc. grew its holdings in Amgen by 153.8% during the 4th quarter. Neville Rodie & Shaw Inc. now owns 3,630 shares of the medical research company’s stock worth $946,000 after acquiring an additional 2,200 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on AMGN shares. Barclays raised their price target on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Bank of America reaffirmed an “underperform” rating and set a $256.00 target price on shares of Amgen in a research report on Tuesday, December 10th. Robert W. Baird reiterated an “underperform” rating and issued a $215.00 price target on shares of Amgen in a research report on Wednesday, September 25th. Cantor Fitzgerald restated an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 price objective on shares of Amgen in a research note on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $318.83.

Amgen Stock Up 1.5 %

Amgen stock traded up $3.97 during mid-day trading on Tuesday, reaching $262.56. The stock had a trading volume of 1,040,952 shares, compared to its average volume of 2,755,155. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The stock’s 50-day simple moving average is $283.46 and its 200-day simple moving average is $310.11. The firm has a market capitalization of $141.13 billion, a PE ratio of 33.62, a price-to-earnings-growth ratio of 2.91 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter last year, the firm posted $4.96 EPS. Amgen’s revenue was up 23.2% compared to the same quarter last year. On average, sell-side analysts forecast that Amgen Inc. will post 19.53 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.63%. The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is currently 121.90%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.